Literature DB >> 20930498

Medical therapy of acromegaly in Turkey.

O Celik1, P Kadioglu.   

Abstract

Acromegaly is associated with multiple co-morbidities and risk of premature mortality. Mortality rate of acromegalic patients is similar to that of the general population when normal GH levels are achieved. Surgery is the mainstay of acromegaly but when surgery fails to achieve disease control, or when surgery is impossible or contraindicated, patients are offered medical therapy and/or radiotherapy. Current medical therapy modalities were revised in this short review.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20930498     DOI: 10.1007/BF03346654

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  50 in total

1.  Effect of octreotide pretreatment on surgical outcome in acromegaly.

Authors:  A Colao; D Ferone; P Cappabianca; M L del Basso De Caro; P Marzullo; A Monticelli; A Alfieri; B Merola; A Calì; E de Divitiis; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  1997-10       Impact factor: 5.958

2.  Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.

Authors:  Marco Losa; Pietro Mortini; Laura Urbaz; Paolo Ribotto; Tristana Castrignanó; Massimo Giovanelli
Journal:  J Neurosurg       Date:  2006-06       Impact factor: 5.115

3.  Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.

Authors:  A Colao; D Ferone; P Marzullo; P Cappabianca; S Cirillo; V Boerlin; I Lancranjan; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

4.  Sandostatin LAR in acromegalic patients: long-term treatment.

Authors:  A K Fløgstad; J Halse; S Bakke; I Lancranjan; P Marbach; C Bruns; J Jervell
Journal:  J Clin Endocrinol Metab       Date:  1997-01       Impact factor: 5.958

5.  Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly.

Authors:  Annamaria Colao; Rosario Pivonello; Renata S Auriemma; Mariano Galdiero; Silvia Savastano; Gaetano Lombardi
Journal:  Eur J Endocrinol       Date:  2007-11       Impact factor: 6.664

6.  Dopamine agonists and pituitary tumor shrinkage.

Authors:  J S Bevan; J Webster; C W Burke; M F Scanlon
Journal:  Endocr Rev       Date:  1992-05       Impact factor: 19.871

Review 7.  Guidelines for acromegaly management: an update.

Authors:  S Melmed; A Colao; A Barkan; M Molitch; A B Grossman; D Kleinberg; D Clemmons; P Chanson; E Laws; J Schlechte; M L Vance; K Ho; A Giustina
Journal:  J Clin Endocrinol Metab       Date:  2009-02-10       Impact factor: 5.958

8.  Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.

Authors:  O Alexopoulou; P Abrams; J Verhelst; K Poppe; B Velkeniers; R Abs; D Maiter
Journal:  Eur J Endocrinol       Date:  2004-09       Impact factor: 6.664

9.  Successful use of weekly pegvisomant administration in patients with acromegaly.

Authors:  C E Higham; J D J Thomas; M Bidlingmaier; W M Drake; P J Trainer
Journal:  Eur J Endocrinol       Date:  2009-05-01       Impact factor: 6.664

10.  Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial.

Authors:  T Lucas; R Astorga
Journal:  Clin Endocrinol (Oxf)       Date:  2006-09       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.